Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
115 participants
INTERVENTIONAL
2009-07-10
2020-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TX2® Low Profile TAA Endovascular Graft
NCT01151020
Zenith® TX2® Low Profile TAA Endovascular Graft
NCT02471781
Post-market Observational Study Zenith® t-Branch™
NCT02104089
Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study
NCT00875563
Zenith(R) Low Profile AAA Endovascular Graft Clinical Study
NCT00833924
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endovascular repair
treatment
Zenith TX2® TAA Endovascular Graft
Endovascular treatment with the study device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zenith TX2® TAA Endovascular Graft
Endovascular treatment with the study device
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Descending thoracic aortic aneurysm with a history of growth greater than or equal to 0.5 cm within the previous 12 months; or
* Descending thoracic aortic degenerative or atherosclerotic ulcers greater than or equal to 10 mm in depth and 20 mm in diameter
Exclusion Criteria
* Other medical condition that may cause the patient to be non-compliant with the protocol, confound the results, or is associated with limited life expectancy (i.e., less than 2 years)
* Pregnant, breast-feeding, or planning on becoming pregnant within 24 months
* Unwilling or unable to comply with the follow-up schedule
* Inability or refusal to give informed consent
* Simultaneously participating in another investigative device or drug study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cook Research Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaiser Permanente
San Francisco, California, United States
University of Denver Colorado
Aurora, Colorado, United States
University of Florida
Gainesville, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
Heart Care Midwest
Peoria, Illinois, United States
Iowa Heart Center
West Des Moines, Iowa, United States
University of Massachusetts
Worcester, Massachusetts, United States
University of Michigan Hospital
Ann Arbor, Michigan, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Cooper University Hospital
Camden, New Jersey, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
New York Hospital of Queens
Flushing, New York, United States
North Shore University Hospital
Manhasset, New York, United States
New York University
New York, New York, United States
Strong Memorial Hospital
Rochester, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
DFW Vascular Group
Dallas, Texas, United States
Baylor University Medical Center at Dallas
Dallas, Texas, United States
The Heart Hospital Baylor Plano
Plano, Texas, United States
University of Virginia Medical Center
Charlottesville, Virginia, United States
Harborview Medical Center
Seattle, Washington, United States
London Health Sciences Centre
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
370024, 2PAS
Identifier Type: -
Identifier Source: secondary_id
08-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.